Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Classical hematology 1

Conditions

Anemia, Iron-Deficiency 2Anemia 2Plexosarcoma 1Neoplasms 1Melanoma 1Lymphoma, Follicular 1Gastrointestinal Stromal Tumors 1Crohn Disease 1Colitis, Ulcerative 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Iron-Dextran Complex × Clear all
NCT06508827 2025-07-09

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Indiana University

Phase 2 Withdrawn
Classical hematologyDermatologic

Anemia, Melanoma, Anemia, Iron-Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡